# Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)

Source: https://welltoldgrants.com/grants/pas-22-196-advancing-research-on-alzheimer-s-disease-ad-and/  
Official notice: https://www.grants.gov/search-results-detail/341289

> National Institutes of Health offered grants of up to $1.8 million to small businesses. Applications closed on September 5, 2025.

| Field | Value |
|---|---|
| Opportunity number | PAS-22-196 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | September 5, 2025 |
| Award ceiling | $1.8 million |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.853, 93.866 |

## Who can apply

- Small businesses

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.

## What the grant funds

This Funding Opportunity Announcement (FOA) invites applications to the National Institute on Aging's (NIA) Small Business Innovation Research (SBIR) program. The aim of this FOA is to support research that may lead to the development of innovative products and/or services that have the potential to advance progress in preventing and treating Alzheimer's disease (AD) and AD-related dementias (ADRD) and/or caring for and treating patients living with AD/ADRD.

## Questions people ask

### Is PAS-22-196 still open?

No. It closed on September 5, 2025.

### Who can apply for Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)?

National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)?

Closed September 5, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $1.8 million each.

### Who has been funded under PAS-22-196?

NIH RePORTER lists 144 projects funded under PAS-22-196 in fiscal 2023 to 2026, at 121 institutions. The most were at Applied Universal Dynamics Corporation, Epicypher, Inc., Artery Therapeutics, Inc.

### Who has won Extramural Research Programs in the Neurosciences and Neurological Disorders grants before?

The largest recipients over five fiscal years were The General Hospital Corporation, The Regents of the University of California, San Francisco, The Johns Hopkins University. The program made 8,641 awards worth $9.1 billion in that time.